Imelda — Clinical Trial Site

61 Registered trials

28 Currently recruiting

Organisation

Imelda

Location

Bonheiden, Belgium

Identifier

ORG-100040025

Address

Imeldalaan 9, 2820, Belgium

Departments

1101: Gastro-enterologie
3002: Neurology
BE10003: Oncologie
Cardiac Surgery
Cardiologie
Cardiology
Center for Reproductive Medicine
Digestive Oncology
Endocrinologie
Endocrinology
Endocrinology and Nephrology
Gastro-enterologie
Gastro-Enterology
Gastro-oncology
Gastroenterology
Gastroenterology & Hepatology
Gastroenterology and Hepatology
GI Clinical Research Center
gynaecology
Imelda GI Clinical Research Center
Imeldaziekenhuis Bonheiden - Department of Gastroenterology
Intensive Care Medicine
Medical Oncology
Medical Oncology and Hematology
N/A
NA
Nephrology
Neurology
Neurology Department
Oncology
Rheumatology
Thoracic and vascular Surgery

Clinical trials at this site (61)

Search interface

A Phase I-IIa Trial on the Safety and Preliminary Effectiveness of Intramyocardial Injection of Allogeneic Cardiac Atrial Stem Cells for the… Not authorised

2024-517031-51-00 Heart Failure 7
A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have compl… Pending

2024-519638-22-00 IgA nephropathy 5
Randomized Evaluation of fleCAinide safety vs. STandard of care in patients with coronary artery disease and Atrial Fibrillation (ReCAST AF)… Pending

2025-525121-13-00 Coronary artery disease 6
A study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with IV Bevacizumab Compared to Standard of Care IV Bevacizumab i… Recruiting

2025-521712-19-00 Colorectal Cancer 5 2026-07-06
A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease Recruiting

2025-522001-38-00 Crohn’s Disease 4 2026-05-27
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 First line triple-negative breast cancer (TNBC) 5 2026-03-19
A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke Recruiting

2024-513911-28-00 Acute Ischemic Stroke 10 2026-03-04
Randomized Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Ade… Recruiting

2024-513317-12-00 Pancreatic cancer 5 2025-02-05
Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting

2023-508304-38-00 Ulcerative Colitis (UC) 4 2024-09-10
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s… Recruiting

2022-501606-35-01 Platinum-sensitive epithelial ovarian, fallopian tube, 11 2024-02-21
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR… Recruiting

2024-512119-34-00 MSI-H/dMMR metastatic colorectal cancer 4 2022-06-20
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or … Recruiting

2025-520672-26-00 Gastrointestinal Neoplasms 9 2025-09-16
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients with Grave’s Disease Recruiting

2024-516020-33-00 Grave’s Disease 4 2025-06-26
A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's… Recruiting

2023-509391-42-00 Chron's Disease 11 2025-06-02
A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 … Recruiting

2024-513441-36-00 MMRp/ MSS colon cancer 4 2024-11-27
Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting

2024-513009-30-00 Moderate to Severe Crohn’s Disease 4 2024-11-21
COMPARE STEMI ONE- Comparison Of reduced DAPT followed by P2Y12 inhibitor Monotherapy with Prasugrel vs stAndard Regimen in STEMI patients t… Recruiting

2024-515883-30-00 St-Elevated Myocardial Infartion 6 2024-08-01
A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting

2023-509096-16-00 Moderately to Severely Active Crohn’s Disease 6 2024-07-31
COLchicine in BElgium in patients with coronary artery disease after Percutaneous Coronary Intervention Recruiting

2023-505028-74-00 Coronary artery disease 5 2024-01-29